Experiment 69417

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationKOHLERT,C: SCHINDLER,G: MARZ,RW: ABEL,G: BRINKHAUS,B: DERENDORF,H: GRAFE,EU: VEIT,M:. (2002). SYSTEMIC AVAILABILITY AND PHARMACOKINETICS OF THYMOL IN HUMANS.. 42(7)
Amount utilized
Compound isolated
DiseaseBOTH THYMOL SULFATE AND GLUCURONIDE EXCRETED IN 24-HOUR URINE WAS 16.2% + 4.5% OF THE DOSE. 24.5 NG ML-1 AND WERE REACHED AFTER 2.0 + 0.8 HOURS. THE MEAN TERMINAL ELIMINATION HALF-LIFE WAS 10.2 HOURS. THYMOL SULFATE WAS DETECTABLE UP TO 41 HOURS AFTER ADMINISTRATION. URINARY EXCRETION COULD BE FOLLOWED OVER 24 HOURS. THE AMOUNT OF ENZYMATIC HYDROLYSIS OF THE METABOLITIES BY HEADSPACE SOLID-PHASE MICROEXTRACTION PRIOR TO GC ANALYSIS AND FLAME IONIZATION DETECTION. THYMOL SULFATE, BUT NOT THYMOL GLUCURONOIDE, WAS DETECTABLE IN PLASMA. PEAK PLASMA CONCENTRATIONS WERE 93.1 + EQUIVALENT TO 1.08 MG THYMOL. NO THYMOL COULD BE DETECTED TO PLASMA OR URINE. HOWEVER, THE METABOLIETES THYMOL SULFATE AND THYMOL GLUCURONIDE WERE FOUND IN URINE AND IDENTIFIED BY LC-MS/MS. PLASMA AND URINE SAMPLES WERE ANALYZED AFTER TO DETERMINE THE SYSTEMIC AVAILABILITY AND THE PHARMACOKINETICS OF THYMOL AFTER ORAL APPLICATION TO HUMANS, A CLINICAL TRAIL WAS CARRIED OUT IN 12 HEALTHY VOLUNTEERS. EACH SUBJECT RECEIVED A SINGLE DOSE OF A BRONCHIPRET TP TABLET, WHICH IS
Dose amount1.08 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES